Effect of Fetal Aortic Valvuloplasty on Outcomes. A Prospective Observational Cohort Study With a Comparison Cohort

Status: Recruiting
Location: See all (13) locations...
Intervention Type: Procedure
Study Type: Observational
SUMMARY

In one of the most severe congenital heart defects, hypoplastic left heart syndrome (HLHS), the left ventricle is underdeveloped and the prognosis is worse than in most other heart defects. The underdevelopment can occur gradually during fetal growth caused by a narrowing of the aortic valve. At some international centers, such fetuses are treated with a balloon dilation of the narrowed valve, but there is no scientifically sound evidence that this treatment is effective. The aim of this study is: 1/ to evaluate whether balloon dilation during the fetal period of a narrowed aortic valve can reduce the risk of the left ventricle becoming underdeveloped and the baby being born with a so-called univentricular heart (HLHS); 2/ to investigate whether such treatment improves the prognosis for this group of children with a very complex and severe heart defect and 3/ to also describe side effects and risks in fetuses and mothers of the fetal procedure.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 5 months
Maximum Age: 7 months
Healthy Volunteers: f
View:

∙ A. All of the following echocardiographic criteria need to be satisfied between 23+0 and 31+6 weeks (z-scores according to Schneider et al):

• Aortic valve stenosis with antegrade flow through the valve

• Predominantly left-to-right shunt at the atrial level

• Predominantly retrograde flow in the aortic arch between the first two brachiocephalic vessels

• Qualitatively depressed left ventricular function

• Left ventricular end-diastolic diameter Z-score \> ±0

• Left ventricular inlet length in diastole :

‣ Gestational age ≤ 24+6: Z-score \> ±0

⁃ Gestational age 25+0 to 27+6: Z-score \> -0.75

⁃ Gestational age ≥ 28+0: Z-score \> -1.50

• Mitral valve diameter in diastole Z-score \> -2.0

∙ B. All of the following postnatal treatment options need to be available: 1. Surgical or catheter based aortic valvotomy 2. Ross-Konno surgery 3. Norwood or hybrid stage-one surgery

Locations
United States
California
Fetal Cardiovascular Program, University of California San Francisco
RECRUITING
San Francisco
Ohio
Congenital Heart Collaborative, Nationwide Children's Hospital
RECRUITING
Columbus
Other Locations
Austria
Kinderherzzentrum Linz
RECRUITING
Linz
Canada
The Hospital for Sick Children Toronto
RECRUITING
Toronto
Finland
Department of Paediatric Cardiology, Helsinki University Children's Hospital
RECRUITING
Helsinki
Germany
Pediatric Cardiology - University Hospital Bonn
RECRUITING
Bonn
Department of Pediatric and Congenital Cardiology, University of Heidelberg
RECRUITING
Heidelberg
University hospital Technical university, mother- and-child center
RECRUITING
Munich
Poland
Department of Perinatal Cardiology and Congenital Anomalies, Centre of Postgraduate Medical Education.
RECRUITING
Warsaw
Spain
Fetal Medicine Unit, Dept. Obstetrics & Gynecology University Hospital 12 de Octubre
RECRUITING
Madrid
Sweden
Department of Pediatric Cardiology, Skane University Hospital
RECRUITING
Lund
Department of pediatric cardiology, Karolinska Institute
RECRUITING
Stockholm
Department of Pediatrics, Umeå University Hospital
RECRUITING
Umeå
Contact Information
Primary
Mats Mellander, Dr, Prof
mats.mellander@vgregion.se
0046705530606
Backup
Annika Öhman, Dr, PhD
annika.ohman@vgregion.se
0046313434568
Time Frame
Start Date: 2021-01-01
Estimated Completion Date: 2029-12-31
Participants
Target number of participants: 200
Treatments
Fetal intervention group
Fetuses with aortic valve stenosis satisfying all of the inclusion/exclusion criteria
Fetal non-intervention group
Fetuses with aortic valve stenosis satisfying all of the inclusion/exclusion criteria which are identical with the criteria in the Fetal intervention group
Sponsors
Leads: Queen Silvia Children's Hospital, Gothenburg, Sweden
Collaborators: Swedish Heart Lung Foundation, Sahlgrenska University Hospital

This content was sourced from clinicaltrials.gov